Recently, the board of directors of Panacea Biotec Pharma Limited has approved the sale of its domestic business assets, which include its pharmaceutical formulations brands in India and Nepal
Cadila Healthcare (Zydus Cadila) said it plans to soon roll out its Covid-19 vaccine ZyCoV-D for the 12-18 age group.Cadila Healthcare (Zydus Cadila) said it plans to soon roll out its Covid-19 vaccine ZyCoV-D for the 12-18 age group.Cadila Healthc
Covid-19 working group of the National Technical Advisory Group on immunisation (NTAGI) is expected to meet on Friday to review trials data of Covovax and Corbevax for their use in children, people in the know said. At present children between the ag
The Union Budget 2022 lays a strong foundation for the ambitious ‘India at 100’ project that has been unveiled. The seven horses of this chariot — PM Gati Shakti, inclusive development, productivity enhancement, sunrise opportunities, energy transiti
The Indian pharmaceutical sector witnessed a 200% increase in foreign direct investment (FDI) in 2020-21, noted the Economic Survey 2021-22. The Indian pharmaceutical sector witnessed a 200% increase in foreign direct investment (FDI) in 2020-21, no
With no immediate plans to use newly approved vaccine Covovax by Serum Institute of India (SII) in the national vaccination drive, 25 crore doses of Covovax will be shipped to Covax facility from next month, people in the know said. With no immediate
Drug maker Cipla said it isn't seeing much demand for drugs such as remdesivir, tocilizumab, favipiravir and certain inhaled corticosteroids that were driving its sales in the second wave of Covid-19, dominated by the Delta variant. Drug maker Cipla
The Indian pharmaceutical sector is the world's third-biggest by volume and makes a substantial contribution to global health.
The Subject Expert Committee (SEC) under India's drug regulator turned down applications by Hetero Labs and Optimus Pharma to launch the generic version of Pfizer's Covid-19 antiviral drug paxlovid without local clinical trials. Both companies had ap
Renuka Ramnath-led private equity (PE) fund Multiples Alternate Asset Management will invest around ₹750 crore to take an about 10% stake in Mumbai-based generic drugs manufacturer BDR Pharmaceuticals, multiple people aware of the development said.ss
, CDSCO.jpg)
